The expanded XS Technology toolbox provides complementary expression systems that deliver reliable, high yielding cGMP processes, thereby addressing the diversity of microbially-derived proteins.
Lonza microbial research and development services head Edwin Davies said the new expansion to XS Technology toolbox, addresses the demand for microbially-derived vaccines and therapeutics.
"Our innovative expression platform offers the versatility of multiple host organisms in conjunction with our proven scale-up processes to allow our customers the opportunity to reduce their developmental hurdles and enter the clinic with a robust, high producing process," Davies added.
The XS Pichia system includes novel strains, inducible promoters and signal sequences for high titers and improved product quality with a production process that is methanol free.
The XS Bacillius system includes novel promoters which drive high titers, without production of endotoxins which improves overall product quality and yield.
Lonza has also developed Pichia expression processes which are methanol free, removing the complication of a solvent based process.